Zymogen Protein C to prevent clotting without bleeding during invasive medical procedures

Duane F Bruley1, Sanjay B Jagannath, Micheal B Streiff

  • 1Synthesizer, Inc., 2773 Westminster Road, Ellicott City, MD 21043, USA. bruley@umbc.edu

Insights

Zymogen Protein C concentrate (ZPC) effectively managed a patient with protein C deficiency and a history of pulmonary embolism who experienced a gastrointestinal bleed. ZPC prevented thrombosis during a critical peri-procedural period.

Area of Science:

  • Hematology
  • Thrombosis and Hemostasis
  • Pharmacology

Background:

  • Thrombophilic disorders, such as Protein C deficiency, significantly increase the risk of Venous Thromboembolism (VTE), a leading cause of death.
  • Protein C deficiency, affecting 1 in 400 Americans, results in approximately half the normal level of endogenous anticoagulant protein C.
  • Patients with Protein C deficiency face a 10-fold increased risk of VTE compared to the general population.

Observation:

  • A 75-year-old male with heterozygous Protein C deficiency and a history of pulmonary embolism developed a life-threatening gastrointestinal bleed post-polypectomy.
  • The bleed occurred while transitioning anticoagulation from Low Molecular Weight Heparin (LMWH) bridge therapy to warfarin.
  • Endoscopic intervention successfully controlled the acute bleeding episode.

Findings:

  • Zymogen Protein C concentrate (ZPC) was administered to prevent thrombosis during the peri-procedural period when anticoagulation was interrupted.
  • The patient received ZPC until anticoagulation with LMWH and warfarin could be safely resumed.
  • Following endoscopic repair and resumption of anticoagulation, the patient remained free of both bleeding and thrombotic events for 16 months.

Implications:

  • Zymogen Protein C concentrate (ZPC) is a viable therapeutic option for peri-procedural management in patients with Protein C deficiency and a history of thromboembolism.
  • This case highlights the successful use of ZPC in preventing thrombosis in a high-risk patient undergoing an invasive procedure.
  • Consideration of ZPC can mitigate the risks associated with managing anticoagulation in complex thrombophilic patients.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation01:06

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...